9 results

A patient in the Aduhelm trial, after an infusion. Photograph: Kayana Szymczak/The New York Times

Drug approval is a remarkably sensitive subject. Pressure from patients – and some doctors – will always be for better treatments for poorly served co(...)

Prof Matt Cooper: ‘If you want to get a drug to patients with these really sad diseases that affect us all eventually, or our families, the more shots on goal there are, whether it be Inflazome or someone else.’

It all began with a chance meeting. Trinity immunologist Professor Luke O’Neill was attending a medical conference in Australia when he bumped into Ma(...)

If your mother already has a diagnosis of Alzheimer’s, it may  be too late to draw up an  enduring power of attorney to ensure that the people she trusts are those making decisions for her should her Alzheimer’s deteriorate

I live and care for my mum, who has been diagnosed with Alzheimer’s but is functioning well and still very lucid. I moved home from abroad to help ou(...)

Biogen said more data had become available after the two aducanumab studies were discontinued, resulting in a new analysis that showed one of the trials met the main goal. Photograph: Reuters

Biogen revived plans on Tuesday to seek US approval for Alzheimer’s treatment aducanumab, surprising investors and saying data from more patients in t(...)

Alzheirmer’s treatment: The Implantation of brain probes was considered too invasive. Photograph: Getty Images

Controlling brainwaves using a flickering LED light may provide a way to halt and then reverse the changes that occur in the brains of Alzheimer’s pat(...)

Whatever one’s feelings about Donald Trump, it pays to remember that in markets, the trend is your friend. Photograph: Brendan McDermid/Reuters

Is euphoria beginning to grip US markets? The Dow Jones has surpassed 19,000. The four main US indices – the S&P 500, Dow, Nasdaq and small-cap (...)

Pfizer: has spiked plans to  expand the  Grange Castle site. Photograph:  Don Emmert/AFP/Getty Images

Pfizer was once synonymous with the treatment of cholesterol. Its Lipitor drug was, for years, the best selling medicine in the world. However, Lipit(...)

“The results of the solanezumab trial were not what we had hoped for and we are disappointed for the millions of people waiting for a potential disease-modifying treatment for Alzheimer’s,” said John Lechleiter, chief executive of Lilly. Photograph: Simone Baribeau/Bloomberg

Eli Lilly said its Alzheimer’s drug had failed in a large clinical trial, sending shares in the US drugmaker tumbling 14 per cent and dealing a big bl(...)

Mary Sutton from Atlantic Philanthropies and Taoiseach Enda Kenny at the launch of the Irish National Dementia Strategy at Government Buildings. Photograph: Gareth Chaney/Collins

Taoiseach Enda Kenny has unveiled a €27.5 million national dementia strategy that will focus on shattering the stigma of the diesase and supporting co(...)